John Steven
Aberdeen, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Functionalization of polymeric nanoparticles with targeting VNAR ligands using vinyl sulfone conjugation.
Journal: Journal of materials chemistry. B
Published: April 24, 2023
In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 19, 2019
Oriented attachment of VNAR proteins, via site-selective modification, on PLGA-PEG nanoparticles enhances nanoconjugate performance.
Journal: Chemical communications (Cambridge, England)
Published: June 18, 2019
Uveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand.
Journal: Translational vision science & technology
Published: December 04, 2018
An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model.
Journal: Frontiers in immunology
Published: August 29, 2018
Anti-ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen-Induced Mouse Model of Rheumatoid Arthritis.
Journal: Journal of immunology research
Published: June 18, 2018
Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development.
Journal: Frontiers in immunology
Published: October 03, 2017
In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development.
Journal: Frontiers in immunology
Published: July 04, 2017
Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis.
Journal: Frontiers in immunology
Published: May 26, 2017
Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development.
Journal: Expert opinion on biological therapy
Published: August 05, 2014
CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
Journal: mAbs
Published: September 03, 2013
Last Updated: 09/26/2026